保利联合(002037) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,196,503,083.68, representing a 21.23% increase compared to ¥986,954,541.40 in the same period last year[5] - The net loss attributable to shareholders was ¥60,359,343.12, a 9.09% improvement from a loss of ¥66,391,753.98 in the previous year[5] - The net profit for the current period is -81,035,045.79, compared to -85,896,140.63 in the previous period, indicating a slight improvement[20] - Operating profit for the current period is -75,705,499.05, an improvement from -81,238,393.77 in the previous period[20] - The total comprehensive income for the current period is -81,035,045.79, compared to -85,653,904.82 in the previous period, showing a slight improvement[21] - The basic and diluted earnings per share are both -0.125, compared to -0.137 in the previous period[21] Cash Flow - The net cash flow from operating activities improved by 24.80%, amounting to -¥239,704,431.36 compared to -¥318,743,125.74 in the same period last year[5] - The cash flow from operating activities shows a net outflow of -239,704,431.36, an improvement from -318,743,125.74 in the previous period[23] - Cash and cash equivalents at the end of the period are 898,668,581.91, compared to 854,548,622.72 at the end of the previous period[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥16,698,290,972.40, a decrease of 2.07% from ¥17,051,184,434.32 at the end of the previous year[5] - The total current assets decreased to CNY 9,365,125,195.30 from CNY 9,727,565,901.94, reflecting a decline of approximately 3.7%[15] - The total liabilities decreased to CNY 13,904,201,738.96 from CNY 14,199,062,510.36, showing a reduction of about 2.1%[17] - The company’s total equity attributable to shareholders decreased by 2.01%, amounting to ¥1,889,243,616.11 compared to ¥1,928,037,170.02 at the end of the previous year[5] Research and Development - Research and development expenses increased by 33.84%, totaling ¥28,000,000.00, driven by an increase in subsidiary R&D projects[8] - Research and development expenses increased to 27,973,094.21 from 20,900,213.28, representing a growth of approximately 33.5%[20] Investment and Financial Activities - The net cash flow from investing activities increased by 46.17%, reaching ¥63,000,000.00, primarily due to reduced fixed asset investments[9] - The company reported a significant increase in credit impairment losses, which rose by 1289.58% to ¥13,315,588.42, mainly due to provisions for bad debts[8] - The company has not reported any investment income for the current period, compared to 417,000.00 in the previous period[23] Operating Costs - The total operating costs for the current period amount to CNY 1,262,791,094.33, up from CNY 1,080,076,819.08 in the previous period, indicating an increase of about 16.9%[19]